Citations

Clear

2429 citation(s) found for "Shah, SS".

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup
Lone, Waseem , Yu, Jiayu , Liu, Xuxiang , Jochum, Dylan T. , Bouska, Alyssa , Shetty, Kunal , Herek, Tyler A. , Sharma, Sunandini , Bi, Chengfeng , Shah, Ab Rauf , Nasser, Zaina W., Amador, Catalina , Arif, Aiza, Mir, Abdul Rouf , Li, Yuping , Heavican‐Foral, Tayla B. , Robinson, Jacob E. , Hyde, R. Katherine , Sakata‐Yanagimoto, Mamiko , Rachagani, Satyanarayana , McKeithan, Timothy W. , Scott, David W. , Staudt, Louis M. , Feldman, Andrew L. , Greiner, Timothy C. , Vose, Julie M. , Khoury, Joseph D. , Chan, Wing C. , Iqbal, Javeed , Lone, Waseem G , Shah, Rauf , Feldman, Andrew L , Greiner, Timothy C , Vose, Julie , Rimsza, Lisa, Khoury, Joseph , Chan, Wing C , Iqbal, Javeed , Scott, David W , Bouska, Alyssa , Amador, Catalina , Jochum, Dylan , Heavican, Tayla B., Robinson, Jacob, Inghirami, Giorgio , Rimsza, Lisa M.

Mayo Clinic

Science Advances | October 17, 2025 | Volume: 11 | Issue: 42 | Pages: No page available

10.1126/sciadv.adx6877 | PMID 41105775 Get It

Peripheral T cell lymphoma (PTCL) is a heterogeneous group of postthymic T cell neoplasms, with ~40% classified as PTCL–not otherwise specified (PTCL-NOS). PTCL-GATA3, a molecularly defined subtype, associated with T helper 2 (T H 2)–like differentiation and poor prognosis, has frequent co-occurrence of TP53 loss/mutation and heterozygous PTEN loss. CD4+ T cell conditional mouse models with Trp53 mutation/deletion and Pten loss demonstrated mature T cell lymphomas (mTCLs) with T H 2-like transcriptomic and immunophenotypic profiles. Molecular studies revealed that codeletion of Trp53/Pten induced T cell receptor and Janus kinase–signal transducer and activator of transcription signaling, promoting T H 2 differentiation while inhibiting T H 1 differentiation. These findings were validated by CRISPR editing of TP53/PTEN loss in human CD4+ T cells and mechanistically evaluated the p53 binding region in intron-3 of GATA3, resulting in transcriptional repression. Transcriptomic profiles of m-TCLs recapitulated human-PTCL-GATA3 transcriptome and distinguished PTCL-NOS subtypes. Preclinical assessment of m-TCLs with PI3Kγ/δ inhibitors significantly improved survival, supporting a therapeutic approach for the p53-aberrant PTCL-GATA3.
Abstract TH208: Evaluating The Accuracy Of Cuffless Devices In Ambulatory Blood Pressure Monitoring: A Systematic Review And Meta-Analysis
Suchday, Pooja , Shah, Heer , Bhanushali, Aditi , Shah, Aalesh, Bajpai, Prakhar, Patel, Nish , Patel, Jay, Bajpai, Prakhar

Mayo Clinic

Hypertension | October 16, 2025 | Volume: 82 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.82.suppl_1.th208 Get It

Introduction: Hypertension is an important modifiable risk factor for cardiovascular diseases. Cuffless blood pressure monitors (CL-BPMs) have emerged as convenient alternatives to traditional cuff-based monitors (C-BPMs). We aim to compare both modalities quantitatively and elaborate on the diagnostic accuracy of CL-BPM. We also discuss the need to address shortcomings of CL-BPMs that limit their current use in widespread clinical practice. Methods: We pooled data from 14 studies that simultaneously compared CL-BPM and C-BPM for ambulatory blood pressure monitoring (ABPM). The results were reported as mean differences (MD) in systolic and diastolic blood pressures (SBP and DBP) between the two modalities. Inverse variance weighted analysis was used to calculate pooled estimates. Tau 2 and I 2 statistics were used to assess heterogeneity. Results: A total of 1011 participants were included. Meta-analysis showed a 24-hour MD of 3.18 [95% CI 1.18-5.19, P=0.002] for SBP and 1.79 [95% CI (-0.43)-4, P=0.11] for DBP, with moderate and high heterogeneity (I 2 = 45% and 78%), respectively. MD in daytime SBP and DBP between the two modalities were 2.52 [95% CI 0.41-4.63, P=0.02] and 0.89 [95% CI (-1.17)-2.96, P=0.4], respectively. An MD of 9.02 [95% CI 4.56-13.49, P<0.0001] was observed for nighttime SBP, whereas it was 6.67 [95% CI 2.59-10.75, P=0.001] for nighttime DBP. Our findings suggest a significant difference in means of 24h SPB, day SBP, night SBP, and DBP between the two modalities, suggesting that cuffless monitors are not on par with cuffed monitors for these measurements. However, there was no significant difference in the means of 24-hour DBP and daytime DBP between the two modalities, suggesting that the cuffless devices were as accurate as the cuffed monitors in these scenarios. Conclusion: CL-BPMs showed an overall significant MD in BP compared to the standard C-BPM. Although the CL-BPM may be convenient, user-friendly, and help eliminate limb-circumference-based cuff sizing, it has some challenges. These include complex calibration protocols; accuracy concerns in several subgroups like individuals with dark skin tone, obesity, and pregnancy; and inability to track BP during sleep, exercise, and while on antihypertensives. Substantial heterogeneity in the results indicates a lack of standardized validation protocols. Detailed studies and subgroup analyses are required to validate these devices before their widespread use in clinical practice.
Primary Lymphoma of the Uterus: Imaging Clues to Diagnosis
Shah, Amar , Lewis, Natasha , Menias, Christine O. , Shah, Amar S , Chen, Longwen

Mayo Clinic

Roentgen Ray Review | October 9, 2025 | Volume: 1 | Issue: 4 | Pages: No page available

10.2214/r3j.24.01053 Get It

Fetal and maternal morbidity in pregnant patients with thrombotic thrombocytopenic purpura: A Nationwide analysis
Eltaher, Basant , Shah, Purva, Antun, Ana G., Masias, Camila , Masias, Camila , Mahmoud, Amir , Sridharan, Meera , Chaturvedi, Shruti

Mayo Clinic

Transfusion | October 8, 2025 | Volume: 65 | Issue: 12 | Pages: 2406-2413

10.1111/trf.18442 | PMID 41058144 Get It

Abstract Background Pregnancy is a known trigger for thrombotic thrombocytopenia purpura (TTP); however, there is limited data on the impact of a TTP diagnosis on pregnancy outcomes. Study design We used retrospective data from the National Inpatient Sample database to identify all hospital admissions of pregnant patients (≥18 years), with and without TTP from 2012 to 2021 using ICD‐9/10 codes. To describe the impact of TTP on maternal and fetal morbidity, we identified different morbidity indicators using standard CDC definitions. Results We identified 7,397,411 pregnancy hospitalizations with a mean age of 29 years. Of these, 233 had TTP , with 73 receiving therapeutic plasma exchange ( TPE ) during admission, which was treated as a surrogate for active TTP . Severe maternal morbidity rates were several‐fold higher in women with TTP (133 per 100 admissions; 95% CI 112–155) compared to those without TTP (6.75 per 100 admissions; 95% CI 6.74–6.79) ( p < 0.001). This included significantly higher rates of acute myocardial infarction, acute renal failure, acute respiratory distress syndrome ( ARDS ), disseminated intravascular coagulation ( DIC ), pulmonary edema/acute heart failure, puerperal cerebrovascular disorders, sepsis, shock, air/thrombotic embolism, blood transfusion, and mechanical ventilation. Amongst fetal outcomes, fetal growth restriction (6.9% vs. 2.3%) was more common in TTP , while there was no statistical difference between the two groups in rates of preterm delivery. In the multivariate analysis, Charlson comorbidity index ( CCI ) ≥ 1 and age ≥ 35 years were associated with higher likelihood of morbidity. Conclusion Pregnancy associated with TTP is associated with inferior maternal and fetal health outcomes.
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Valtis, Yannis K. , Lin, Chenyu , Devlin, Sean, Curran, Kevin J., Wang, Xiuyan , Jeyakumar, Nikeshan , Miller, Katharine, Zhang, Amy , Darobi, Ali Al, Sasine, Joshua , Kopmar, Noam E. , Tsai, Stephanie B., Solh, Melhem , Tan, Virginia, Ramakrishnan, Aravind , Shaughnessy, Paul , Mountjoy, Luke , Hoeg, Rasmus T. , Schwartz, Marc S. , Tracy, Sean , Moore, Jozal , Bobillo, María Silvina Odstrcil , Connor, Matthew P. , Ladha, Abdullah , Sutherland, Katherine C. , Muffly, Lori , Park, Jae H. , Shah, Nirali N , Jeyakumar, Nikeshan , Sasine, Joshua , Advani, Anjali S , Chen, Evan , Hilal, Talal , Shah, Bijal , Faramand, Rawan , Bezerra, Evandro D , Dykes, Kaitlyn C , Logan, Aaron C , Moore, Jozal , Odstrcil Bobillo, Silvina , Frey, Noelle V , Connor, Matthew , Ladha, Abdullah , Dholaria, Bhagirathbhai R , Sutherland, Katherine , Roloff, Gregory W , Muffly, Lori , Lin, Chenyu , Nemirovsky, David , Rejeski, Kai , Curran, Kevin Joseph , Kota, Vamsi , Muhsen, Ibrahim N. , Aldoss, Ibrahim , Advani, Anjali S. , Reshef, Ran , Tsai, Stephanie B., Hilal, Talal , Shah, Bijal , Faramand, Rawan , Bezerra, Evandro D. , Battiwalla, Minoo , Mathews, John Abraham , Dykes, Kaitlyn C. , Kumaran, Muthu Sendhil , Schwartz, Marc, Frey, Noelle V. , Dholaria, Bhagirathbhai , Roloff, Gregory W.

Mayo Clinic

Blood Advances | October 6, 2025 | Volume: 10 | Issue: 1 | Pages: 276-288

10.1182/bloodadvances.2025017526 | PMID 41052404 Get It

Abstract Chimeric antigen receptor (CAR) T-cell (CAR-T) treatment for B-cell acute lymphoblastic leukemia (ALL) induces high initial response rates, but most patients relapse. Low disease burden (often defined as &lt;5% blasts in the bone marrow) is associated with better outcomes. CAR HEMATOTOX (HT) is a score using prelymphodepletion hematologic and inflammatory parameters to predict outcomes in lymphoma. Here, we assess its prognostic utility in a large multicenter adult B-cell ALL cohort. Patients who received brexucabtagene autoleucel across 33 centers in North America were included as part of the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) consortium. An independent cohort of 61 patients with ALL treated with an investigational CD19 CAR-T therapy at 1 center was also described. Among 199 ROCCA consortium patients, 43 (22%) patients with HTlow scores had lower rates of delayed neutrophil recovery than those with HThigh scores (26% vs 52%, P = .002) and fewer severe infections (2.5% vs 18.8%, P = .011). They also had higher response rates, overall survival (OS), and event-free survival (EFS), as well as lower nonrelapse mortality and cumulative incidence of relapse. The survival differences remained significant after multivariable adjustment for disease burden and other covariates. In the investigational cohort of 61 patients, patients with HTlow scores had improved OS and EFS, as well as higher peak CAR-T expansion. In summary, CAR HT score is a prognostic factor independent of disease burden in adult ALL. HTlow score is associated with superior outcomes after CD19 CAR-Ts and higher CAR-T expansion in a single-center cohort. These trials were registered at www.clinicaltrials.gov as #NCT01044069 and #NCT01860937.
Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment
Lee, Ikjae , Jang, Grace E. , Sherman, Alexander , Johnston, Wendy , Fernandes, Joseph Americo, Habib, Ali A. , Maragakis, Nicholas J. , Shah, Jaimin , Zinman, Lorne , Floeter, Mary Kay, Ajroud‐Driss, Senda , Gwathmey, Kelly , Heiman‐Patterson, Terry , Jawdat, Omar, Kasarskis, Edward J. , Kisanuki, Yaz Y. , Wymer, James , Fournier, Christina , Hayat, Ghazala , Heitzman, Daragh, Lomen‐Hoerth, Catherine , Pulley, Michael , Scelsa, Stephen N. , Walk, David , Shoesmith, Christen , Sorenson, Eric J. , Elman, Lauren , Harms, Matthew , Hoover, Benjamin N., Yun, RN ByoungSook, Santella, Regina M. , Mitsumoto, Hiroshi , Group, for the PLS NHS Study, Diaz, Frank , Maragakis, Nicholas , Oskarsson, Björn , Goutman, Stephen A , Sorenson, Eric, Walk, David , Cheung, Ken , Diaz, Frank , Fernandes, J. Americo, Paganoni, Sabrina , Burke, Katherine M. , Oskarsson, Björn , Goutman, Stephen A. , Simmons, Zachary , Harms, Matthew B. , Hoover, Benjamin N., Group, for the PLS NHS Study

Mayo Clinic

Annals of Neurology | September 29, 2025 | Volume: 99 | Issue: 2 | Pages: 418-428

10.1002/ana.78056 | PMID 41020440 Get It

Objective The primary lateral sclerosis ( PLS ) consensus diagnostic criteria and functional rating scale ( PLSFRS ) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study ( PLS NHS ) to understand their performance in this prospective cohort. Methods The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2–4 years); and definite PLS (4–15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3‐, 6‐, 9‐, and 12‐month follow‐up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed‐effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models. Results A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS . Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27–0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year ( p = 0.001). Interpretation In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2026;99:418–428
Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits
Shaw, Vikram R. , Byun, Jinyoung , Thrift, Aaron P. , Zhu, Catherine , Li, Donghui , Kelley, Robin Kate , Bracci, Paige M. , Bucur, Roxana , Knox, J. David, Jalal, Prasun K. , Ghobrial, R. Mark , Nguyen, Mindie H. , Parikh, Neehar D. , Wu, Hui‐Chen , El‐Serag, Hashem, Chang, Ping , Chun, Yun Shin , Gu, Jian , Huff, Chad D. , Rashid, Asif, Hwang, Lu‐Yu, Khaderi, Saira, Roberts, Lewis R. , Hassan, Manal M. , Shaw, Vikram R , Byun, Jinyoung , Thrift, Aaron P , Permuth, Jennifer B , Yuan, Jian-Min , Nguyen, Mindie H , Kim, Richard , Gu, Jian , Kaseb, Ahmed O , McGlynn, Katherine A , Roberts, Lewis R , Parikh, Neehar D , Jalal, Prasun K , Han, Younghun , Hatia, Rikita , Cleary, Sean P. , Lok, Anna S. , Permuth, Jennifer B. , Knox, Jennifer, Singal, Amit G. , Kono, Yuko , Shah, Dimpy P. , Kim, Richard D. , El‐Serag, Hashem B. , Rashid, Asif , Klein, Alison P. , McGlynn, Katherine A. , Amos, Christopher I.

Mayo Clinic

International Journal of Cancer | September 27, 2025 | Volume: 158 | Issue: 5 | Pages: 1193-1203

10.1002/ijc.70136 | PMID 41013983 Get It

Abstract Hepatocellular carcinoma (HCC) mortality is increasing globally, partly due to the growing prevalence of nonviral liver diseases. Genome‐wide association studies (GWAS) have identified genetic variants associated with HCC development. Leveraging GWAS summary statistics and linkage disequilibrium score regression (LDSR), we investigated disease co‐development with hepatitis C virus‐negative (HCV‐negative) HCC to provide unique insights into HCC etiology and prioritize relationships for further causal inquiry. We utilized the LDSR statistical framework to estimate the genetic correlation and heritability between HCV‐negative HCC with 901 epidemiologic, behavioral, and clinical traits from the United Kingdom Biobank (UKBB). First, we set the threshold for observed scale heritability of each trait at 0.02 to ensure reliable inferences with adequate study power. Next, we observed significant positive genetic correlations between HCV‐negative HCC and blood‐based biomarkers of liver injury (ALT, GGT) and allostatic load (including glycated hemoglobin, blood pressure, and total albumin). We also identified a positive genetic correlation between HCV‐negative HCC and diseases associated with metabolic dysfunction‐associated steatotic liver disease (MASLD), including diabetes, hypertension, chronic ischemic heart disease, and others. Taken together, our results help to identify polygenic and pleiotropic signals related to different phenotypic traits associated with HCC and support further exploration of the predictive power of blood‐based biomarkers identified in this study for inferring HCC development among HCV‐negative individuals.
Prognostic value of Nectin-4 and Trop2 extracellular vesicles for plasma and urine samples collected from patients with bladder cancer just prior to cystectomy
Bauer, Emily, Thapa, Prabin , Frank, Igor, Shah, Paras , Cheville, John C. , Orme, Jacob J. , Jang, Albert, Kim, Yohan , Lucien, Fabrice

Mayo Clinic

International Journal of Cancer Care and Delivery | September 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.53876/001a.129600 Get It

Paper 30: The Impact of Femoral Version on the Outcomes of Hip Arthroscopic Surgery for Femoroacetabular Impingement: Results of a Multicenter Prospective Cohort Study
Shah, Vivek P. , Nepple, Jeffrey J. , Spiker, Andrea M. , Levy, Bruce A. , Yen, Yi-Meng, Clohisy, John C. , Westermann, Robert W. , Krych, Aaron J. , Yen, Yi‐Meng

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 26, 2025 | Volume: 13 | Issue: 9_suppl3 | Pages: No page available

10.1177/2325967125s00087 Get It

Objectives: The role of femoral version (FV[MOU1] ) in the pre-arthritic hip pain remains increasingly recognized, including in femoroacetabular impingement (FAI). Increased femoral version or decreased femoral version may play a role in hip biomechanics contributing to hip instability or impingement, respectively. The purpose of this study was to compare the outcomes of hip arthroscopy for FAI across different femoral version groups in a multicenter prospective cohort study. Methods: A prospective multicenter cohort study of 677 FAI patients undergoing primary hip arthroscopy was performed. The current study included 603 patients with low-dose CT performed preoperatively for measurement of femoral version from the larger cohort. Inclusion criteria were patients aged 14-45 years with idiopathic FAI. Exclusion criteria were previous ipsilateral hip procedures, associated disorders, or Tönnis 2 or greater osteoarthritis. Femoral version was measured on low-dose computed tomography (CT) utilizing the Yoshioka oblique method and was broken into five subgroups: <5° (decreased FV), 6-15° (normal FV), 16-25° (mildly increased FV), 26-35° (moderately increased FV), 35°+ (severely increased FV). Patient-reported outcomes (PROs) were measured at a minimum one-year follow-up. The modified Harris hip score (mHHS) was assessed relative to the minimal clinically important difference (MCID) of 8 and patient acceptable symptom state (PASS) of 74. Additional PROs included the HOOS Pain and Sports/Recreation subscores and the iHOT-12 score. Composite failure was defined as a reoperation for persistent symptoms or a failure to achieve either the mHHS MCID or PASS. Independent t-test (Mann-Whitney U) and ANOVA were utilized to compare groups. Results: Males had statistically lower femoral version than females (14.0° vs 18.0°; p<0.001). In females, 38.0% had mildly increased FV, 17.9% had moderately increased FV, and 3.6% had severely elevated FV. This is compared to 27.6%, 9.2%, and 1.8% in males, respectively (all p<0.001). Decreased FV was present in 7.1% of males, compared to 5.9% of females. Increased or decreased femoral versions appear to have similar outcomes to normal version when evaluated by PROs or outcome states. In fact, mildly increased and moderate increased FV group demonstrated the best outcomes. Changes in HOOS pain and sports subscores were significantly higher for these groups. Severely increased FV, >35°, was only present in 2.8% of patients but did demonstrate a higher rate of composite failure (15.4%) compared to moderately increased FV (3.1%). The decreased FV group had a composite failure of 10.4% compared to normal femoral version, 16-25° (10.2%). Conclusions: In a patient cohort undergoing hip arthroscopy for FAI, significant differences in FV between males and females were present. Overall, in a multicenter prospective cohort study, the outcomes of hip arthroscopy for FAI did not seem to differ between increased or decreased femoral versions but were superior in mild to moderately increased FV. Future research with longer-term follow-up is still needed to definitively establish the longevity of outcomes of hip arthroscopy relative to FV.
297: Itraconazole Exposure in Patients Receiving Extracorporeal Membrane Oxygenation
Martin, Nate, Brinkman, Hannah, Seelhammer, Troy, Stevens, Ryan, Kim, MJ, Shah, Adi, Wieruszewski, Patrick, Martin, Nate, Brinkman, Hannah, Seelhammer, Troy, Stevens, Ryan, Kim, MJ, Shah, Adi, Wieruszewski, Patrick

Mayo Clinic

ASAIO Journal | September 26, 2025 | Volume: 71 | Issue: Supplement 4 | Pages: 35-35

10.1097/01.mat.0001169056.09544.df Get It